Isomorphic Labs secures $5bn in major UK tech funding round

Tech17 minutes ago

London-based artificial intelligence drug discovery firm Isomorphic Labs has raised $5bn, equivalent to £3.8bn, in a Series C funding round described as one of the largest in British technology history. The oversubscribed investment was announced on Tuesday and co-led by US venture capital firms Greenoaks and Sequoia Capital. The move signals strong investor confidence in the potential of AI to transform the pharmaceutical sector, with billions committed to the company’s ongoing development.

The round included participation from Andreessen Horowitz, Alphabet, Thrive Capital, MGX, GV, Capital G, Temasek, and the UK government’s Sovereign AI Fund. This investment follows reports that the company was seeking a valuation of up to $50bn, a significant increase from its previous valuation of approximately $17.5bn. Although the company has not disclosed its post-money valuation, the raise brings its total disclosed external funding since 2025 to roughly $7.7bn, following a $2.1bn Series B round secured just six months earlier.

AI minister Kanishka Narayan welcomed the announcement, praising the company’s work for its potential to fundamentally change how new medicines are discovered. He noted that the UK government’s Sovereign AI Fund made a follow-on investment to support the firm’s global growth. Founded in 2021 by Nobel Prize-winning scientist Sir Demis Hassabis, Isomorphic uses its proprietary drug design engine, IsoDDE, to predict molecular interactions and reduce the time and cost of drug development. The firm is developing treatments for cancer and immune disorders in partnership with major pharmaceutical companies including Eli Lilly, Novartis, and Johnson & Johnson.

Despite the substantial capital injection, Isomorphic has not yet begun testing its own drug candidates in humans. The company remains in late-stage preclinical development, with early results described as encouraging across its internal oncology and immunology programmes. The new funding will be used to support the development of AI models, expand the drug pipeline, and construct global bioengineering infrastructure in preparation for clinical trials. Hassabis stated that the round enables the company to accelerate progress and drive its first therapeutic programmes towards clinical trials to deliver tangible impact for patients.

Post Disclaimer

The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.

This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.

The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.

Our Socials

Recent Posts

Stockmark.1T logo with computer monitor icon from Stockmark.it
Loading Next Post...
Loading

Signing-in 3 seconds...

Signing-up 3 seconds...